CG Oncology vs MSA Safety

CG Oncology (CGON), health care, and MSA Safety (MSA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

CG Oncology is worth $7.1B on the stock market and MSA Safety $6.7B: CG Oncology is valued at 6% more. CG Oncology's operating margin in its latest fiscal year was -4722% and MSA Safety's 19.8%. Over the past year CG Oncology's share price has moved +99.2% and MSA Safety's +8.64%.

Key facts

CG Oncology market value
$7.1B
MSA Safety market value
$6.7B
MSA Safety P/E
22.2
CG Oncology revenue
$4MFY to 2025-12-31
MSA Safety revenue
$1.9BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

CG Oncology vs MSA Safety: every measure side by side
Measure CG Oncology MSA Safety
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.1Bhigher$6.7Blower
Revenue$4Mlower$1.9Bhigher
Earnings-$161Mlower$278.9Mhigher
Employees142lower5,300higher
Total assets$791.6Mlower$2.6Bhigher
Valuation
P/E—22.2
P/S1745higher3.6lower
P/B7.1higher4.7lower
Dividend yield0.00%lower1.26%higher
Profitability
Operating margin-4722%lower19.8%higher
Balance sheet
Net assets$752.6Mlower$1.4Bhigher
Total liabilities$39Mlower$1.2Bhigher
Total debt$3Mlower$580.9Mhigher
Cash on hand$32.5Mlower$165.1Mhigher
Price change
Today-6.89%lower+1.38%higher
1 year+99.2%higher+8.64%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

CG Oncology only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. · Who owns MSA

Further comparisons

Learn

Questions and answers

Which is bigger, CG Oncology or MSA Safety?

By market value, CG Oncology is the larger: $7.1B against $6.7B for MSA Safety. By revenue in its latest fiscal year, MSA Safety is the larger: $1.9B against $4M for CG Oncology.

Which has the higher operating margin?

MSA Safety: 19.8%, against -4722% for CG Oncology. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

MSA Safety: 1.26%, against 0.00% for CG Oncology. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

MSA Safety: $580.9M, against $3M for CG Oncology. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both CG Oncology and MSA Safety?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold CG Oncology and 4 hold MSA Safety.

Cite this page

Funkfolio, “CG Oncology vs MSA Safety”, data as of 17 November 2026. https://funkfolio.com/compare/cgon-vs-msa

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.